ASND – Ascendis Pharma A/S
Float Short %
5.71
Margin Of Safety %
Put/Call OI Ratio
0.31
EPS Next Q Diff
1.59
EPS Last/This Y
4.36
EPS This/Next Y
6.8
Price
228.64
Target Price
266.01
Analyst Recom
1.18
Performance Q
13.99
Relative Volume
1.98
Beta
0.43
Ticker: ASND
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | ASND | 209.1 | 0.19 | 0.17 | 14457 |
| 2025-12-29 | ASND | 211.02 | 0.20 | 0.17 | 14528 |
| 2025-12-30 | ASND | 209.61 | 0.20 | 0.43 | 14688 |
| 2025-12-31 | ASND | 213.33 | 0.20 | 0.86 | 14754 |
| 2026-01-02 | ASND | 213.43 | 0.23 | 0.36 | 15963 |
| 2026-01-05 | ASND | 213.17 | 0.25 | 0.55 | 16710 |
| 2026-01-06 | ASND | 209.35 | 0.27 | 3.69 | 17330 |
| 2026-01-07 | ASND | 212.9 | 0.29 | 0.24 | 17576 |
| 2026-01-08 | ASND | 208.52 | 0.29 | 0.69 | 17953 |
| 2026-01-09 | ASND | 202.78 | 0.30 | 0.50 | 18027 |
| 2026-01-12 | ASND | 208.93 | 0.28 | 0.26 | 19702 |
| 2026-01-13 | ASND | 214.96 | 0.27 | 0.05 | 19848 |
| 2026-01-14 | ASND | 217.5 | 0.26 | 0.47 | 20173 |
| 2026-01-15 | ASND | 215.25 | 0.26 | 0.00 | 20269 |
| 2026-01-16 | ASND | 205.69 | 0.27 | 2.95 | 19639 |
| 2026-01-20 | ASND | 215.28 | 0.28 | 0.12 | 12088 |
| 2026-01-21 | ASND | 216.78 | 0.31 | 0.72 | 12695 |
| 2026-01-22 | ASND | 228.67 | 0.31 | 0.42 | 12727 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | ASND | 208.89 | 77.7 | 375.5 | -3.22 |
| 2025-12-29 | ASND | 211.10 | 77.7 | 381.8 | -3.22 |
| 2025-12-30 | ASND | 209.48 | 77.7 | 378.3 | -3.22 |
| 2025-12-31 | ASND | 213.29 | 77.7 | 384.0 | -3.22 |
| 2026-01-02 | ASND | 213.29 | 77.7 | 380.2 | -3.22 |
| 2026-01-05 | ASND | 213.24 | 77.7 | 380.3 | -3.22 |
| 2026-01-06 | ASND | 209.30 | 77.7 | 377.4 | -3.22 |
| 2026-01-07 | ASND | 212.44 | 77.7 | 384.7 | -3.22 |
| 2026-01-08 | ASND | 208.65 | 77.7 | 377.1 | -3.22 |
| 2026-01-09 | ASND | 202.82 | 77.7 | 375.7 | -3.22 |
| 2026-01-12 | ASND | 208.86 | 79.0 | 387.7 | -3.22 |
| 2026-01-13 | ASND | 215.04 | 79.0 | 388.0 | -3.22 |
| 2026-01-14 | ASND | 217.44 | 72.2 | 383.9 | -3.22 |
| 2026-01-15 | ASND | 215.27 | 72.2 | 379.4 | -3.22 |
| 2026-01-16 | ASND | 205.76 | 70.0 | 372.5 | -3.22 |
| 2026-01-20 | ASND | 215.45 | 63.9 | 391.1 | -3.22 |
| 2026-01-21 | ASND | 216.76 | 58.1 | 382.2 | -3.22 |
| 2026-01-22 | ASND | 228.64 | 58.1 | 392.6 | -3.22 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | ASND | 0.00 | 1.83 | 5.60 |
| 2025-12-29 | ASND | 0.00 | 1.84 | 5.60 |
| 2025-12-30 | ASND | 0.00 | 1.84 | 5.60 |
| 2025-12-31 | ASND | 0.00 | 1.84 | 5.60 |
| 2026-01-02 | ASND | 0.00 | 1.84 | 5.60 |
| 2026-01-05 | ASND | 0.00 | 1.78 | 5.60 |
| 2026-01-06 | ASND | 0.00 | 1.78 | 5.60 |
| 2026-01-07 | ASND | 0.00 | 1.78 | 5.60 |
| 2026-01-08 | ASND | 0.00 | 1.78 | 5.60 |
| 2026-01-09 | ASND | 0.00 | 1.78 | 5.60 |
| 2026-01-12 | ASND | 0.00 | 1.78 | 5.60 |
| 2026-01-13 | ASND | 0.00 | 1.78 | 5.71 |
| 2026-01-14 | ASND | 0.00 | 1.78 | 5.71 |
| 2026-01-15 | ASND | 0.00 | 1.78 | 5.71 |
| 2026-01-16 | ASND | 0.00 | 1.78 | 5.71 |
| 2026-01-20 | ASND | 0.00 | 1.60 | 5.71 |
| 2026-01-21 | ASND | 0.00 | 1.60 | 5.71 |
| 2026-01-22 | ASND | 0.00 | 1.60 | 5.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.17
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
0.42
Insider Transactions
Institutional Transactions
1.6
Beta
0.43
Average Sales Estimate Current Quarter
245
Average Sales Estimate Next Quarter
277
Fair Value
Quality Score
32
Growth Score
56
Sentiment Score
95
Actual DrawDown %
0.6
Max Drawdown 5-Year %
-60.5
Target Price
266.01
P/E
Forward P/E
55.07
PEG
P/S
19.39
P/B
P/Free Cash Flow
EPS
-4.25
Average EPS Est. Cur. Y
-3.22
EPS Next Y. (Est.)
3.59
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-35.52
Relative Volume
1.98
Return on Equity vs Sector %
106.6
Return on Equity vs Industry %
122.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.17
EBIT Estimation
392.6
Ascendis Pharma A/SSector: Healthcare
Industry: Biotechnology
Employees: 1017
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today
news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance
stock history ASND – Ascendis Pharma A/S invest stock market
stock prices ASND premarket after hours
ticker ASND fair value insiders trading